COM:KARUNATX
Karuna Therapeutics, Inc.
- Stock
Last Close
329.74
15/03 20:00
Market Cap
12.60B
Beta: -
Volume Today
1.28M
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|---|
average inventory | 10.44M - | 24.61M 135.62% | 14.16M 42.44% | |||||
average payables | 533.50K - | 408K 23.52% | 706K 73.04% | 1.40M 98.58% | 2.16M 53.99% | 4.58M 112.18% | ||
average receivables | 875K - | 903.50K 3.26% | 28.50K 96.85% | |||||
book value per share | -1.80 - | 8.43 567.86% | 32.61 286.90% | 12.82 60.70% | 17.23 34.43% | 35.61 106.68% | 33.94 4.70% | |
capex per share | -0.00 - | -0.01 593.53% | -0.01 20.84% | -0.02 64.75% | -0.11 565.42% | -0.03 72.56% | -0.08 172.82% | |
capex to depreciation | -13 - | -22 69.23% | -1.98 90.99% | -2.89 45.74% | -6.07 110.10% | -0.82 86.45% | -1.71 108.41% | |
capex to operating cash flow | 0.00 - | 0.01 165.91% | 0.00 56.68% | 0.01 61.29% | 0.03 407.71% | 0.00 86.82% | 0.01 88.40% | |
capex to revenue | -0.08 - | -0.09 3.50% | -4.46 5,085.10% | |||||
cash per share | 0.26 - | 8.33 3,083.29% | 32.56 290.91% | 12.19 62.57% | 16.95 39.09% | 35.54 109.63% | 34.17 3.86% | |
days of inventory on hand | ||||||||
days payables outstanding | ||||||||
days sales outstanding | 17.28 - | 1.96 88.68% | ||||||
debt to assets | 5.48 - | 0.00 99.98% | 0.00 52.02% | 0.01 1,359.45% | 0.01 84.09% | 0.00 67.79% | 0.01 172.69% | |
debt to equity | -0.87 - | 0.00 100.13% | 0.00 52.11% | 0.01 1,385.05% | 0.01 88.66% | 0.00 68.35% | 0.01 181.25% | |
dividend yield | ||||||||
earnings yield | -0.04 - | -0.08 98.29% | -0.05 38.17% | -0.03 48.74% | -0.04 47.64% | -0.04 18.02% | -0.04 16.62% | |
enterprise value | 158.29M - | 132.10M 16.55% | 692.21M 424.00% | 2.64B 280.85% | 3.62B 37.23% | 5.97B 65.08% | 11.53B 93.04% | |
enterprise value over ebitda | -32.94 - | -9.12 72.30% | -16.14 76.95% | -38.48 138.35% | -25.27 34.32% | -20.62 18.42% | -23.38 13.41% | |
ev to operating cash flow | -39.31 - | -8.59 78.14% | -22.38 160.57% | -37.74 68.59% | -35.86 4.97% | -26.19 26.96% | -29.88 14.08% | |
ev to sales | 97.87 - | 561.45 473.65% | 17.63K 3,039.77% | |||||
free cash flow per share | -0.54 - | -1.43 162.20% | -2.60 81.84% | -2.66 2.38% | -3.57 34.25% | -7.24 102.88% | -10.52 45.32% | |
free cash flow yield | -0.03 - | -0.07 162.20% | -0.03 51.68% | -0.03 24.07% | -0.03 4.11% | -0.04 35.26% | -0.03 9.78% | |
graham net net | -1.83 - | 8.25 551.48% | 32.30 291.73% | 11.86 63.29% | 16.48 38.93% | 34.81 111.30% | 31.95 8.23% | |
graham number | 5.74 - | 17.48 204.59% | 52.45 200.04% | 27.34 47.88% | 43.74 59.98% | 83.66 91.28% | 94.66 13.14% | |
income quality | 0.67 - | 0.88 31.53% | 0.70 19.88% | 1.02 44.85% | 0.70 31.16% | 0.83 17.62% | 0.89 7.82% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | 0 | 0 | |
interest coverage | -4.10 - | -5.62 36.87% | -48.05 755.32% | -20.43 - | ||||
interest debt per share | 1.73 - | 0.25 85.71% | 0.10 60.98% | 0.10 5.30% | 0.26 153.62% | 0.62 139.51% | 0.45 26.78% | |
inventory turnover | ||||||||
invested capital | -0.87 - | 0.00 100.13% | 0.00 52.11% | 0.01 1,385.05% | 0.01 88.66% | 0.00 68.35% | 0.01 181.25% | |
market cap | 148.57M - | 217.52M 46.41% | 900.93M 314.17% | 2.69B 198.21% | 3.82B 42.08% | 6.22B 62.82% | 11.70B 88.22% | |
net current asset value | -13.38M - | 91.31M 782.43% | 389.60M 326.68% | 335.90M 13.78% | 491.69M 46.38% | 1.12B 127.31% | 1.23B 10.35% | |
net debt to ebitda | -2.02 - | 5.90 391.74% | 4.87 17.49% | 0.74 84.90% | 1.39 89.53% | 0.84 39.79% | 0.34 59.11% | |
net income per share | -0.81 - | -1.61 98.29% | -3.75 132.67% | -2.59 30.88% | -4.94 90.38% | -8.74 77.03% | -11.73 34.31% | |
operating cash flow per share | -0.54 - | -1.42 160.81% | -2.59 82.72% | -2.64 2.15% | -3.46 31.06% | -7.21 108.23% | -10.44 44.81% | |
payables turnover | ||||||||
receivables turnover | 21.12 - | 186.61 783.49% | ||||||
research and ddevelopement to revenue | 3.47 - | 21.08 507.85% | 556.73 2,540.81% | |||||
return on tangible assets | -2.83 - | -0.19 93.32% | -0.11 39.75% | -0.20 72.84% | -0.27 38.19% | -0.24 12.84% | -0.32 36.63% | |
revenue per share | 1.27 - | 0.34 73.49% | 0.02 94.74% | |||||
roe | 0.45 - | -0.19 142.38% | -0.12 39.86% | -0.20 75.87% | -0.29 41.62% | -0.25 14.34% | -0.35 40.92% | |
roic | 3.36 - | -0.15 104.60% | -0.12 23.10% | -0.21 75.88% | -0.28 33.31% | -0.26 7.95% | -0.38 50.27% | |
sales general and administrative to revenue | 1.42 - | 7.15 402.37% | 200.81 2,708.11% | |||||
shareholders equity per share | -1.80 - | 8.43 567.86% | 32.61 286.90% | 12.82 60.70% | 17.23 34.43% | 35.61 106.68% | 33.94 4.70% | |
stock based compensation to revenue | 0.81 - | 4.46 453.13% | 114.07 2,456.99% | |||||
tangible asset value | -13.37M - | 91.57M 784.99% | 389.92M 325.81% | 338.93M 13.08% | 502.03M 48.12% | 1.13B 124.34% | 1.25B 11.37% | |
tangible book value per share | -1.80 - | 8.43 567.86% | 32.61 286.90% | 12.82 60.70% | 17.23 34.43% | 35.61 106.68% | 33.94 4.70% | |
working capital | -9.39M - | 91.41M 1,073.08% | 389.75M 326.37% | 337.75M 13.34% | 497.12M 47.19% | 1.12B 125.46% | 1.25B 11.27% |
All numbers in USD (except ratios and percentages)